RxDoctor Payments Data

Morgan Storey

Family · Little Rock, ARNPI 1063866341

Payments from drug & device makers

$2,201in general payments, 2019–2025

Across 54 payments — averaging $40.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Astellas Pharma US Inc$372
  • 180 Medical, Inc.$142
  • Rochester Medical Corporation$139
  • Teleflex LLC$123
  • Sumitomo Pharma America, Inc.$113
  • plus $294 from 7 others

What the payments were for

  • Consulting fees$78836%
  • Food & beverage$1,09350%
  • Education$32015%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)12$1,018
Astellas Pharma US Inc8$372
180 Medical, Inc.6$142
Rochester Medical Corporation8$139
Teleflex LLC1$123
Sumitomo Pharma America, Inc.5$113
Medtronic4$110
Urovant Sciences Inc3$72
Coloplast2$35
Merck2$31
Shionogi Inc1$24
Viiv Healthcare Company1$18
Ambu Inc.1$3

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,201 in reported general payments places this provider in the 80th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$47,189
Medicare patients
165
Services billed
856

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron74$44,717
MyrbetriqMirabegron85$37,006
Estradiol112$7,309
Trospium Chloride72$4,936
Methenamine Hippurate60$3,573
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst43$552
Cephalexin60$426
Tamsulosin Hcl29$208
Fluconazole26$188
Ciprofloxacin Hcl13$44
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$113$44,71774 claims
Astellas Pharma US IncMyrbetriq$372$37,00685 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,103 family providers in Arkansas.

Other family in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →